NCT05792007Recruiting
Study of the Medullary Microenvironment in Acute Childhood Leukemia
Etude du Microenvironnement médullaire Dans Les Leucémies Aiguës de l'Enfant
Source: ClinicalTrials.gov · Last updated 24 Nov 2025
Brief summary (registry, in English)
Acute leukemia (AL) is the most common cancer in children. Despite the optimization of chemotherapy treatments and the development of supportive care, a certain number of LAs relapse and/or progress to death of the child. It therefore seems essential to try to better understand the physiopathology and the mechanisms of resistance to treatment of these diseases.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 8 Mar 2023
- Start date
- 26 Oct 2023
- Primary completion date
- 25 Oct 2026
- Lead sponsor
- University Hospital, Tours
- NCT number
- NCT05792007
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 26 Oct 2023 to the primary completion date, 25 Oct 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- for patients with AL:
- Patient under 1 year old and over 15 years old.
- Contraindication to myelogram.
- Absence of signature of the informed consent by the 2 parents or the holder of parental authority.
- Patients with relapsed acute lymphoblastic or myeloblastic leukemia.
- Having received prior hematological treatments.
- Parents with physical or mental condition not allowing to understand the informed consent.
- Control group patients
- Patient under 1 year old and over 15 years old.
- Having an underlying haematological pathology.
- Absence of signature of the informed consent by the 2 parents or the holder of parental authority.
- Having received prior hematological treatments.
- Parents with physical or mental condition not allowing to understand informed consent.
Who the study is looking for
- for patients with AL:
- Child with acute lymphoblastic or myeloblastic leukemia at diagnosis
- Not having received prior hematological treatment
- Aged 1 to 15 years old
- Whose 2 parents, or the holder of parental authority, have signed a consent enlightened.
- Affiliated patient or beneficiary of a social security scheme.
- Control group patients:
- Child undergoing orthopedic surgery exposing the bone marrow (osteotomy of the pelvis).
- Aged between 1 and 15 years old.
- Having no pathology of hematological origin.
- Not having received any treatment that could interfere with the functioning of the bone marrow.
- Whose 2 parents or the holder of parental authority have signed a consent enlightened.
- Affiliated patient or beneficiary of a social security scheme.
Age in the registry: 1 year to 15 years · Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Service de chirurgie orthopédique pédiatrique -CHRU TOURS Coordinator of this site? Confirm its status | Tours | France | Recruiting |
| Service d'onco-hématologie pédiatrique -CHRU Tours Coordinator of this site? Confirm its status | Tours | France | Recruiting |
| Service d'hématologie biologique-CHRU TOURS Coordinator of this site? Confirm its status | Tours | France | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.